Published in J Clin Oncol on February 23, 2004
Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients. Clin Cancer Res (2009) 1.94
Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol (2013) 1.19
A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients. World J Urol (2010) 1.08
Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res (2009) 1.02
Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One (2012) 1.00
Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: a systematic review and practice guideline. Can Urol Assoc J (2007) 0.99
Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med (2011) 0.96
Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer (2014) 0.91
An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer (2006) 0.91
Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol (2005) 0.89
Chemotherapy in metastatic renal cell cancer. World J Urol (2005) 0.88
Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy. Clin Dev Immunol (2013) 0.87
Analysis of changes in the total lymphocyte and eosinophil count during immunotherapy for metastatic renal cell carcinoma: correlation with response and survival. J Korean Med Sci (2007) 0.84
Immunotherapy in metastatic renal cell carcinoma. World J Urol (2005) 0.84
Effective modulation of CD4(+)CD25 (+high) regulatory T and NK cells in malignant patients by combination of interferon-α and interleukin-2. Cancer Immunol Immunother (2012) 0.83
C-reactive Protein in Patients with Metastatic Clear Cell Renal Carcinoma: An Important Biomarker for Tumor-associated Inflammation. Biomark Insights (2007) 0.83
Clinical outcome and prognostic survival factors in patients with advanced renal cell carcinoma treated with very low-dose interleukin-2, interferon-alpha, and tegafur-uracil: a single-institution experience. Int J Clin Oncol (2008) 0.83
Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma. Br J Cancer (2012) 0.83
Better survival with interleukin-2-based regimens? Possibly only in highly selected patients. J Clin Oncol (2004) 0.81
Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy. PLoS One (2012) 0.81
Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Semin Oncol (2015) 0.81
Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma. Can Urol Assoc J (2007) 0.80
Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One (2014) 0.79
Minimal changes in the systemic immune response after nephrectomy of localized renal masses. Urol Oncol (2014) 0.78
Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component. J Cancer Res Clin Oncol (2013) 0.78
Current status and perspective of antiangiogenic therapy for cancer: urinary cancer. Int J Clin Oncol (2006) 0.77
Effect of an immunomodulatory regimen for cancer prevention: A case report. Mol Clin Oncol (2016) 0.75
Role of cytokine therapy for renal cell carcinoma in the era of targeted agents. Curr Oncol (2009) 0.75
Nonmyeloablative allogeneic stem cell transplantation in metastatic renal cell carcinoma: a new therapeutic option or just a clinical experiment? World J Urol (2005) 0.75
Phosphorothioate analogs of oligodeoxynucleotides: inhibitors of replication and cytopathic effects of human immunodeficiency virus. Proc Natl Acad Sci U S A (1987) 5.17
Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol (2007) 3.61
Betaine improves the PCR amplification of GC-rich DNA sequences. Nucleic Acids Res (1997) 3.32
Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature (1982) 3.26
Antiviral effects of recombinant tumour necrosis factor in vitro. Nature (1986) 3.25
Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 3.22
The immunobiology of zinc. Immunol Today (1997) 2.93
High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis (1998) 2.48
Association between clinical disease activity and Epstein-Barr virus reactivation in MS. Neurology (2000) 2.46
Expression of human herpesvirus 8-encoded cyclin D in Kaposi's sarcoma spindle cells. J Natl Cancer Inst (1997) 2.40
Evidence of suppressor cell activity in spleens of mice bearing primary tumors induced by Moloney sarcoma virus. J Exp Med (1974) 2.40
An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A (2001) 2.28
Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol (1997) 2.28
Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer (2003) 2.18
Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum. J Immunol (1975) 2.13
Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective. Ann Oncol (2008) 2.12
Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res (2001) 2.12
Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood. Int J Cancer (1997) 2.11
Genetic variability between isolates of human immunodeficiency virus (HIV) type 2 is comparable to the variability among HIV type 1. Proc Natl Acad Sci U S A (1988) 2.07
Interferon-gamma production by Listeria monocytogenes-specific T cells active in cellular antibacterial immunity. Eur J Immunol (1983) 2.06
Acoustic and mechanical properties of artificial stones in comparison to natural kidney stones. J Urol (2000) 2.05
MIB-1 immunohistochemistry in clinical stage I nonseminomatous testicular germ cell tumors predicts patients at low risk for metastasis. Cancer (1997) 2.04
Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia (2005) 1.99
EVIDENCE FOR AN UNSTABLE CO(2) FIXATION PRODUCT IN ALGAL CELLS. Proc Natl Acad Sci U S A (1957) 1.97
Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer (1986) 1.95
Laparoscopic nephrectomy: the experience of the laparoscopy working group of the German Urologic Association. J Urol (1998) 1.93
Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology (2001) 1.92
Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project. Eur Urol (2002) 1.91
Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol (1999) 1.88
Expression and growth-promoting function of the IL-8 receptor beta in human melanoma cells. J Immunol (1996) 1.86
Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex. J Virol (2000) 1.85
Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies. Lancet (1990) 1.80
Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol (1998) 1.80
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79
Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med (1999) 1.79
High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol (2004) 1.70
Seroprevalence of human herpesvirus-8 (HHV-8) in countries of Southeast Asia compared to the USA, the Caribbean and Africa. Br J Cancer (1999) 1.68
Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J Virol (2001) 1.68
Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. Transfus Med (2000) 1.67
Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66
Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood (2000) 1.65
Subcutaneous penile vein thrombosis (Penile Mondor's Disease): pathogenesis, diagnosis, and therapy. Urology (2006) 1.63
A dihydroxyboryl-substituted methacrylic polymer for the column chromatographic separation of mononucleotides, oligonucleotides, and transfer ribonucleic acid. Biochemistry (1973) 1.62
Inhibition of proliferation of lymphoma cells and T lymphocytes by suppressor cells from spleens of tumor-bearing mice. J Immunol (1975) 1.62
Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology (2000) 1.61
Failure to detect human cytomegalovirus DNA in peripheral blood leukocytes of healthy blood donors by the polymerase chain reaction. Transfusion (1992) 1.60
Quality of life of living kidney donors in Germany: a survey with the Validated Short Form-36 and Giessen Subjective Complaints List-24 questionnaires. Transplantation (2004) 1.59
VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res (2000) 1.58
Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: evaluation of long-term treatment effects. Ann Oncol (2005) 1.58
Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma. J Clin Oncol (1995) 1.58
Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand (1988) 1.57
Successful living related kidney transplantation despite renal angiomyolipoma in situ. J Urol (1999) 1.57
Interferon treatment inhibits onset of herpes simplex virus immediate-early transcription. Virology (1988) 1.55
Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol (1996) 1.55
Interleukin-12 inhibits apoptosis in chronic lymphatic leukemia (CLL) B cells. Cancer Biother Radiopharm (2002) 1.55
Protection by remote ischemic preconditioning during coronary artery bypass graft surgery with isoflurane but not propofol - a clinical trial. Acta Anaesthesiol Scand (2011) 1.53
New agents for treatment of advanced transitional cell carcinoma. Ann Oncol (2006) 1.53
Two functionally distinct anti-tumor effector cells isolated from primary murine sarcoma virus-induced tumors. J Immunol (1976) 1.53
Effects of sildenafil on cAMP and cGMP levels in isolated human cavernous and cardiac tissue. Urology (2000) 1.50
Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol (1992) 1.50
The buccal mucosal graft for urethral reconstruction: a preliminary report. J Urol (1992) 1.49
The "music" of core-shell spheres and hollow capsules: influence of the architecture on the mechanical properties at the nanoscale. Nano Lett (2008) 1.49
Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: results of a prospective phase I trial. Int J Hyperthermia (2007) 1.48
Idiopathic anterior urethritis in prepubertal and pubertal boys: pathology and clues to etiology. Urology (1998) 1.47
Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma. Ann Oncol (1991) 1.47
Altered cytokine production in the elderly. Mech Ageing Dev (1998) 1.47
Polyclonal immunoglobulin secretion by human B lymphocytes exposed to Epstein-Barr virus in vitro. J Immunol (1979) 1.46
Isoforms of prostate-specific antigen in serum: a result of the glycosylation process in dysplastic prostatic cells? Prostate (1996) 1.46
Production of immune interferon by murine T-cell clones from long-term cultures. Nature (1981) 1.45
Single potential analysis of cavernous electrical activity in spinal cord injury patients. J Urol (1994) 1.43
Symptomatic and quality of life response to tolterodine in subgroups of men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia. World J Urol (2009) 1.43
Uncircumcision: a historical review of preputial restoration. Plast Reconstr Surg (1998) 1.43
Laparoscopic radical cystectomy with continent urinary diversion (rectal sigmoid pouch) performed completely intracorporeally: the initial 5 cases. J Urol (2001) 1.42
IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer (2001) 1.42
Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol (2001) 1.41
Ileocecal valve reconstruction during continent urinary diversion. J Urol (1994) 1.41
Production of cytokines in acute schizophrenic psychosis. Biol Psychiatry (1996) 1.41
Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma--results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol (2001) 1.41
[From "schizophrenia" to "disturbance of the integrity of the self": causes and consequences of renaming schizophrenia in Japan in 2002]. Nervenarzt (2011) 1.41
Laparoscopic partial nephrectomy: initial experience and comparison to the open surgical approach. J Urol (1995) 1.40
[An interuniversity comparison of the supervision of doctoral candidates--should the promotion procedures be changed?]. Dtsch Med Wochenschr (2000) 1.40
Aetiology, diagnosis and management of spontaneous perirenal haematomas. Eur Urol (1996) 1.39
Long-term results of internal urethrotomy. J Urol (1996) 1.39
IL-6 independent monocyte/B cell defect in renal transplant recipients with long-term stable graft function. Transplantation (1994) 1.39
Use of hydro-jet cutting for laparoscopic partial nephrectomy in a porcine model. Urology (2001) 1.39
Complications of laparoscopic procedures in urology: experience with 2,407 procedures at 4 German centers. J Urol (1999) 1.39
Concentrations of lysosomal cysteine proteases are decreased in renal cell carcinoma compared with normal kidney. J Cancer Res Clin Oncol (1997) 1.38